Postmenopausal state | Age
Item
elderly postmenopausal women (ages 55 and older)
boolean
C0232970 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Osteopenia DXA scan T score | Osteoporosis
Item
osteopenic (dxa t-score -1.0 to -2.5 sd). however, after full counseling about the risks, benefits, and options regarding therapy for osteoporosis and discussion with her pcp, an osteoporotic woman may enroll in the study.
boolean
C0029453 (UMLS CUI [1,1])
C2584897 (UMLS CUI [1,2])
C0029456 (UMLS CUI [2])
Breast Carcinoma | Aromatase Inhibitors
Item
with breast cancer on aromatase inhibitor therapy
boolean
C0678222 (UMLS CUI [1])
C0593802 (UMLS CUI [2])
Distant metastasis Absent BMD | Osteoporosis Absent BMD
Item
with no evidence of distant metastatic disease or osteoporosis (by bmd or clinical history)
boolean
C1269798 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0177804 (UMLS CUI [1,3])
C0029456 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0177804 (UMLS CUI [2,3])
Operative Surgical Procedures | Therapeutic radiology procedure | Aromatase Inhibitors
Item
type of surgical procedure or addition of radiation therapy prior to this aromatase inhibitor therapy will not exclude patients
boolean
C0543467 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0593802 (UMLS CUI [3])
Informed Consent
Item
participants must provide voluntary, written informed consent to participate in the study, which includes understanding of the procedures, medications, and risks and benefits
boolean
C0021430 (UMLS CUI [1])
Breast Carcinoma TNM clinical staging
Item
women with stage 4 breast cancer (presence of distant metastases)
boolean
C0678222 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Gender | Bone density Normal DXA T score
Item
women with normal bone density by dxa (t-score > -1.0 sd)bone density by dxa, except in the instance of a fragility fracture.
boolean
C0079399 (UMLS CUI [1])
C1272809 (UMLS CUI [2,1])
C0205307 (UMLS CUI [2,2])
C2584897 (UMLS CUI [2,3])
Gender | Illness Affecting Bone metabolism | Illness Affecting Mineral metabolism | Kidney Failure | eGFR | Liver Failure | Malignant Neoplasms | Breast Carcinoma Excluded | Superficial basal cell carcinoma Treated Excluded | Squamous cell carcinoma Treated Excluded | Primary Hyperparathyroidism untreated | Malabsorption
Item
women with history of any illness known to affect bone and mineral metabolism, such as renal failure (estimated gfr <30), hepatic failure, malignancy (excluding breast cancer, treated superficial basal and squamous cell carcinoma and malignancies where the diagnosis itself or its treatment would not adversely affect bone metabolism), untreated primary hyperparathyroidism, and malabsorption.
boolean
C0079399 (UMLS CUI [1])
C0221423 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0596204 (UMLS CUI [2,3])
C0221423 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0678715 (UMLS CUI [3,3])
C0035078 (UMLS CUI [4])
C3811844 (UMLS CUI [5])
C0085605 (UMLS CUI [6])
C0006826 (UMLS CUI [7])
C0678222 (UMLS CUI [8,1])
C2828389 (UMLS CUI [8,2])
C0862889 (UMLS CUI [9,1])
C1522326 (UMLS CUI [9,2])
C2828389 (UMLS CUI [9,3])
C0007137 (UMLS CUI [10,1])
C1522326 (UMLS CUI [10,2])
C2828389 (UMLS CUI [10,3])
C0221002 (UMLS CUI [11,1])
C0332155 (UMLS CUI [11,2])
C0024523 (UMLS CUI [12])
Gender | Glucocorticoids Oral | Therapeutic immunosuppression | Anticonvulsants Affecting Bone metabolism | Phenobarbital | Phenytoin | Carbamazepine
Item
women being treated with oral glucocorticoid therapy >3 months for suppression therapy, and certain anti-seizure medications which may adversely affect bone metabolism (phenobarbital, phenytoin, carbamazepine).
boolean
C0079399 (UMLS CUI [1])
C0017710 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0021079 (UMLS CUI [3])
C0003286 (UMLS CUI [4,1])
C0392760 (UMLS CUI [4,2])
C0596204 (UMLS CUI [4,3])
C0031412 (UMLS CUI [5])
C0031507 (UMLS CUI [6])
C0006949 (UMLS CUI [7])
Peptic Ulcer untreated
Item
those with untreated active peptic ulcer disease
boolean
C0030920 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
Osteoporosis localized to spine BMD DXA T score | Osteoporosis Hip BMD DXA T score | History of fragility fracture Adult
Item
those with osteoporosis by bmd (t-score -2.5 sd at the spine or total hip) or a history of fragility fracture as an adult. however, as discussed above, osteoporotic women may elect to enroll in the study.
boolean
C0587229 (UMLS CUI [1,1])
C0177804 (UMLS CUI [1,2])
C2584897 (UMLS CUI [1,3])
C0029456 (UMLS CUI [2,1])
C0019552 (UMLS CUI [2,2])
C0177804 (UMLS CUI [2,3])
C2584897 (UMLS CUI [2,4])
C1272068 (UMLS CUI [3,1])
C0001675 (UMLS CUI [3,2])
Diphosphonates Oral | Calcitonin measurement | Washout Period
Item
women treated with oral bisphosphonates or calcitonin for 3 months within the last year (3 month washout period)
boolean
C0012544 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0201924 (UMLS CUI [2])
C1710661 (UMLS CUI [3])
Gender | Children
Item
men and children will be excluded because they do not get postmenopausal osteoporosis following treatment with an aromatase inhibitor
boolean
C0079399 (UMLS CUI [1])
C0008059 (UMLS CUI [2])
Gender | Poor dental hygiene Very | Tooth Extraction Patient need for
Item
women with very poor dental hygiene (as assessed by the baseline dental exam) in need of dental extraction during the study
boolean
C0079399 (UMLS CUI [1])
C0457640 (UMLS CUI [2,1])
C0442824 (UMLS CUI [2,2])
C0040440 (UMLS CUI [3,1])
C0686904 (UMLS CUI [3,2])
Fluorides | Fluorides Dental care Excluded
Item
use of fluoride for more than 1 month ever (except for dental treatment)
boolean
C0016327 (UMLS CUI [1])
C0016327 (UMLS CUI [2,1])
C0011331 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])
Evaluation Vertebrae Quantity
Item
less than 2 evaluable vertebrae
boolean
C1261322 (UMLS CUI [1,1])
C0549207 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Distant metastasis
Item
distant metastatic disease
boolean
C1269798 (UMLS CUI [1])